Compare KIDS & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | ZVRA |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.4M | 562.2M |
| IPO Year | 2016 | 2015 |
| Metric | KIDS | ZVRA |
|---|---|---|
| Price | $22.10 | $12.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $24.67 | $23.00 |
| AVG Volume (30 Days) | 178.5K | ★ 791.8K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | $98,049,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $14.07 | $37.27 |
| Revenue Next Year | $11.85 | $53.42 |
| P/E Ratio | ★ N/A | $17.13 |
| Revenue Growth | 37.95 | ★ 350.91 |
| 52 Week Low | $14.42 | $7.16 |
| 52 Week High | $26.74 | $15.04 |
| Indicator | KIDS | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 62.06 |
| Support Level | $17.54 | $12.18 |
| Resistance Level | $26.74 | $14.27 |
| Average True Range (ATR) | 0.84 | 0.38 |
| MACD | -0.45 | 0.11 |
| Stochastic Oscillator | 7.14 | 83.05 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.